Abbott Labs Files 8-K on Operations and Financials

Ticker: ABT · Form: 8-K · Filed: 2024-07-18T00:00:00.000Z

Sentiment: neutral

Topics: regulatory-filing, financial-condition, operations

Related Tickers: ABT

TL;DR

Abbott Labs filed its 8-K for July 18, 2024, covering operations and financials. No major surprises yet.

AI Summary

Abbott Laboratories filed an 8-K on July 18, 2024, to report on its results of operations and financial condition, as well as to file financial statements and exhibits. The filing does not contain specific financial figures or details about operational changes, but serves as a formal notification of these items to the SEC.

Why It Matters

This filing is a routine update for investors and the market, indicating that Abbott Laboratories is providing necessary financial and operational information as required by regulatory bodies.

Risk Assessment

Risk Level: low — This is a standard regulatory filing with no new material information or significant events disclosed.

Key Players & Entities

FAQ

What specific financial results or operational updates are being reported by Abbott Laboratories in this 8-K filing?

The filing indicates that it pertains to 'Results of Operations and Financial Condition' and 'Financial Statements and Exhibits,' but it does not provide specific figures or details within the provided text.

What is the exact date of the earliest event reported in this 8-K?

The date of the earliest event reported is July 18, 2024.

Under which section of the Securities Exchange Act of 1934 is this 8-K report filed?

This 8-K report is filed pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.

What is Abbott Laboratories' principal executive office address?

Abbott Laboratories' principal executive office is located at 100 Abbott Park Road, Abbott Park, Illinois 60064-6400.

What is the IRS Employer Identification Number for Abbott Laboratories?

The IRS Employer Identification Number for Abbott Laboratories is 36-0698440.

From the Filing

0001628280-24-032182.txt : 20240718 0001628280-24-032182.hdr.sgml : 20240718 20240718073735 ACCESSION NUMBER: 0001628280-24-032182 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 16 CONFORMED PERIOD OF REPORT: 20240718 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240718 DATE AS OF CHANGE: 20240718 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ABBOTT LABORATORIES CENTRAL INDEX KEY: 0000001800 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 360698440 STATE OF INCORPORATION: IL FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-02189 FILM NUMBER: 241123710 BUSINESS ADDRESS: STREET 1: 100 ABBOTT PARK ROAD CITY: ABBOTT PARK STATE: IL ZIP: 60064-3500 BUSINESS PHONE: 2246676100 MAIL ADDRESS: STREET 1: 100 ABBOTT PARK ROAD CITY: ABBOTT PARK STATE: IL ZIP: 60064-3500 8-K 1 abt-20240718.htm 8-K abt-20240718 0000001800 FALSE New York Stock Exchange Chicago Stock Exchange, Inc. 0000001800 2024-07-18 2024-07-18 0000001800 exch:XNYS 2024-07-18 2024-07-18 0000001800 exch:XCHI 2024-07-18 2024-07-18 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 _______________________________________________________ FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 July 18, 2024 Date of Report (Date of earliest event reported) ABBOTT LABORATORIES (Exact name of registrant as specified in charter) _______________________________________________________ Illinois 1-2189 36-0698440 (State or other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification  No.) _______________________________________________________ 100 Abbott Park Road Abbott Park , Illinois 60064-6400 (Address of principal executive offices)(Zip Code) Registrant’s telephone number, including area code: ( 224 ) 667-6100 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities Registered Pursuant to Section 12(b) of the Act: Title of Each Class Trading Symbol(s) Name of Each Exchange on Which Registered Common Shares, Without Par Value ABT New York Stock Exchange Chicago Stock Exchange, Inc. Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company o If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o Item 2.02    Results of Operations and Financial Condition On July 18, 2024, Abbott Laboratories announced its results of operations for the second quarter 2024. Furnished as Exhibit 99.1, and incorporated herein by reference, is the news release issued by Abbott announcing those results. In that news release, Abbott uses various non-GAAP financial measures including, among others, net earnings excluding specified items. These non-GAAP financial measures adjust for factors that are unusual or unpredictable, such as expenses primarily associated with acquisitions, a divestiture, restructuring actions, cost reduction initiatives, fair value adjustment

View on Read The Filing